You are here

DNA APTAMER ARRAYS FOR DETECTION OF CANCER BIOMARKERS

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: N43CO0800044
Agency Tracking Number: N43CO0800044
Amount: $149,975.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: 2008
Award Year: 2008
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
PHYSICAL SCIENCES INC 20 NEW ENGLAND BUSINESS CENTER
ANDOVER, MA 01810
United States
DUNS: 073800062
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Anton Chestukhin
 () -
Business Contact
Phone: (978) 689-0003
Email: sasso@psicorp.com
Research Institution
N/A
Abstract

The major goal of cancer proteomics is detection and identification of human tumors based on 'protein signatures' characteristic for different malignancies, Early tumor detection is critical for effective treatment and patient survival. Simultaneous identification of multiple cancer specific protein biomarkers in body fluids would dramatically increase specificity and accuracy of cancer detection and diagnosis. Protein microarrays where protein detection is performed by antibodies are promising new tools. However, the limiting factor for wider use of protein arrays is availability of specific antibodies and their stability. We propose to use DNA aptamers for capturing and detection of cancer.related biomarkers which are present in blood and urine, Aptamers are excellent alternatives for antibodies because they are easier to isolate and more stable than antibodies. Aptamers specific against protein biomarkers could be rapidly and cost effectively synthesized and used for diagnostic procedures. The proposed Phase I effort is focused on demonstration of the feasibility of the proposed technology for detection of ovarian cancer-specific biomarkers. Successful completion of the Phase I will set the stage for further development and commercialization of the proposed technology to result in clinically relevant diagnostics.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government